Stronger warning about potential hepatotoxicity in patients taking Duract (bromfenac)

March 1998

    The FDA is requiring a stronger warning about potential hepatotoxicity in patients taking Duract (bromfenac).
    Duract is the new NSAID that just came out last fall. It's approved only for short-term use...similar to Toradol (ketorolac).

    Now there are several reports of severe hepatitis and liver failure in patients taking Duract for longer than a month.

    Don't prescribe Duract for more than 10 days. If patients take it longer, monitor LFTs...particularly ALT and bilirubin.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote